Biotech firm Terray Therapeutics lands $120m Series B
The capital infusion will be used to progress internal programs into clinical trials and further enhance Terray’s integrated AI platform, tNova.
The capital infusion will be used to progress internal programs into clinical trials and further enhance Terray’s integrated AI platform, tNova.
Copyright PEI Media
Not for publication, email or dissemination